Immunosuppressant indulges EBV reactivation and related lymphoproliferative disease by inhibiting Vδ2(+) T cells activities after hematopoietic transplantation for blood malignancies

BACKGROUND: Following the extensive use of immunosuppressive drugs in the clinic, immunosuppression-associated side effects have received increasing attention. Epstein-Barr virus (EBV) reactivation and related lymphoproliferative diseases (LPD) are the lethal complications observed after allogeneic...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Jiangying, Gao, Haitao, Xu, Lan-Ping, Mo, Xiao-Dong, Liu, Ruoyang, Liang, Shuang, Wu, Ning, Wang, Ming, Wang, Zhidong, Chang, Ying-Jun, Wang, Yu, Zhang, Xiao-Hui, Huang, Xiao-Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Immune Cell Therapies and Immune Cell Engineering
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7206968/
https://www.ncbi.nlm.nih.gov/pubmed/32221014
http://dx.doi.org/10.1136/jitc-2019-000208

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7206968/
https://www.ncbi.nlm.nih.gov/pubmed/32221014
http://dx.doi.org/10.1136/jitc-2019-000208

Ejemplares similares